-
Mashup Score: 5ASCO GU 2020: STAMPEDE Trial - Comparative Quality of Life in Patients Randomized Contemporaneously to Docetaxel of Abiraterone - 5 year(s) ago
ASCO GU 2020 comparing quality of life results in patients randomized in the STAMPEDE trial, pivotal study in cementing novel drug combinations in the standard of care of localized and advanced prostate cancer
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 1Treatment Options for Bacillus Calmette-Guérin (BCG) Refractory Bladder Cancer Disease - Wassim Kassouf - 5 year(s) ago
Ashish Kamat is joined by Wassim Kassouf, an expert in the bladder cancer field on Bacillus Calmette-Guérin unresponsive disease. Together they discuss the different treatment options in these patients, how the shortage of BCG will affect patient samples in clinical studies, and how to counsel patients with BCG-unresponsive carcinoma in situ. Biographies: Wassim Kassouf, MD, CM, FRCSC, is a…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Treatment options for Bacillus Calmette-Guérin #BCG refractory #BladderCancer disease. Wassim Kassouf, MD @mcgillu joins @UroDocAsh @MDAndersonNews in a discussion on UroToday > https://t.co/3A0gi0gUrp #GU20 @ASCO https://t.co/xqjITVGejm
-
-
Mashup Score: 0
Phil Koo, MD is joined by Wolfgang Weber, MD sharing his thoughts on the current state of PSMA based therapies. Dr. Weber discusses which patients respond well to this treatment, as well as the research being done to better understand why some patients do not respond well to this treatment. Dr. Weber concludes with a glimpse of things to come for PSMA based therapies. Biographies: Wolfgang…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Targeted radionuclide therapy of #ProstateCancer. Wolfgang Weber, MD @TU_Muenchen joins @PhillipKooMD sharing his thoughts on the state of #PSMA based therapies. #WartchNow on UroToday > https://t.co/3Tq9RcLc5k @ASCO #GU20 https://t.co/YRUztSyTGh
-
-
Mashup Score: 0
Phil Koo, MD, and Wolfgang Weber, MD, to share his thoughts on the current state of PSMA based therapies. Dr. Weber discusses which patients respond well to this treatment, as well as the research being done to better understand why some patients do not respond well to this treatment. Dr. Weber concludes with a glimpse of things to come for PSMA based therapies. Biographies: Wolfgang Weber, MD…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Targeted radionuclide therapy of #ProstateCancer. Wolfgang Weber, MD @TU_Muenchen joins @PhillipKooMD sharing his thoughts on the state of #PSMA based therapies. #WartchNow on UroToday > https://t.co/3Tq9RcLc5k @ASCO #GU20 https://t.co/idQsEZmKog
-
-
Mashup Score: 0Treatment Options for Bacillus Calmette-Guérin (BCG) Refractory Bladder Cancer Disease - Wassim Kassouf - 5 year(s) ago
Ashish Kamat is joined by Wassim Kassouf, an expert in the bladder cancer field on Bacillus Calmette-Guérin unresponsive disease. Together they discuss the different treatment options in these patients, how the shortage of BCG will affect patient samples in clinical studies, and how to counsel patients with BCG-unresponsive carcinoma in situ. Biographies: Wassim Kassouf, MD, CM, FRCSC, is a…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Treatment options for Bacillus Calmette-Guérin #BCG refractory #BladderCancer disease. Wassim Kassouf, MD @mcgillu joins @UroDocAsh @MDAndersonNews in a discussion on UroToday > https://t.co/3A0gi0gUrp #GU20 @ASCO https://t.co/nFqnxdUjS6
-
-
Mashup Score: 0
Phil Koo, MD, and Wolfgang Weber, MD, to share his thoughts on the current state of PSMA based therapies. Dr. Weber discusses which patients respond well to this treatment, as well as the research being done to better understand why some patients do not respond well to this treatment. Dr. Weber concludes with a glimpse of things to come for PSMA based therapies. Biographies: Wolfgang Weber, MD…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Targeted radionuclide therapy of #ProstateCancer. Wolfgang Weber, MD @TU_Muenchen joins @PhillipKooMD sharing his thoughts on the state of #PSMA based therapies. #WartchNow on UroToday > https://t.co/3Tq9RcLc5k @ASCO #GU20 https://t.co/mjZrxXF9GT
-
-
Mashup Score: 0Treatment Options for Bacillus Calmette-Guérin (BCG) Refractory Bladder Cancer Disease - Wassim Kassouf - 5 year(s) ago
Ashish Kamat is joined by Wassim Kassouf, an expert in the bladder cancer field on Bacillus Calmette-Guérin unresponsive disease. Together they discuss the different treatment options in these patients, how the shortage of BCG will affect patient samples in clinical studies, and how to counsel patients with BCG-unresponsive carcinoma in situ. Biographies: Wassim Kassouf, MD, CM, FRCSC, is a…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Treatment options for Bacillus Calmette-Guérin #BCG refractory #BladderCancer disease. Wassim Kassouf, MD @mcgillu joins @UroDocAsh @MDAndersonNews in a discussion on UroToday > https://t.co/3A0gi0gUrp #GU20 @ASCO https://t.co/XodDKm8TQn
-
-
Mashup Score: 0Prostate cancer: high-res ultrasound vs MRI imaging - 5 year(s) ago
Laurence Klotz, MD, Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto, Toronto, Canada, discusses a prospective analysis comparing…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ProstateCancer: high-res ultrasound vs MRI imaging w/ Laurence Klotz of @Sunnybrook: https://t.co/I5EnCCiGOd #GU20 @ASCO @ASTRO_org #UroSoMe #UroOnc #PCsm #GUsm
-
-
Mashup Score: 0CaboPoint: second-line cabozantinib for RCC - 5 year(s) ago
Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses the CaboPoint trial (NCT03945773). This study focuses on cabozantinib as…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: CaboPoint: second-line cabozantinib for #RCC w/ @AlbigesL of @GustaveRoussy: https://t.co/6vllgZcil6 #GU20 @ASCO @ASTRO_org #UroSoMe #UroOnc #KCsm #GUsm
-
-
Mashup Score: 0Prostate active surveillance - 5 year(s) ago
Jeff Tosoian, MD, MPH, Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, discusses the use of active…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: Prostate active surveillance w/ @UroDocJT of @UMich: https://t.co/Q5llLl478X #GU20 @ASCO @ASTRO_org #UroSoMe #UroOnc #PCsm
-
#STAMPEDE trial - Comparative quality of life in patients randomized contemporaneously to docetaxel of abiraterone. @HannahR08378281 @MRCCTU. @ASCO #GU20 written coverage by @anis_a_hamid @DanaFarber. #ReadNow on UroToday > https://t.co/EtwblEuCyj #ProstateCancer https://t.co/39LNgMOcWc